Microbot Medical Q2 2026 Earnings Report

Microbot Medical EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.08
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Microbot Medical Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.33 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Microbot Medical Announcement Details

• Quarter: Q2 2026
• Date: 8/11/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, August 13, 2026
• Conference Call Time: 4:00PM ET

Microbot Medical (NASDAQ:MBOT) (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease. The endoluminal platform targets gastrointestinal and urogenital tracts, employing swallowable or catheter-deployed microbots to biopsy tissue, administer local therapy or assist in endoscopic procedures.

Headquartered in Ra’anana, Israel, with U.S. operations in Boston, Massachusetts, Microbot Medical collaborates with leading academic and clinical research centers to advance its pipeline through preclinical studies and early-stage human trials. Under the leadership of CEO Ohad Arazi, the company seeks regulatory approvals and strategic partnerships to bring its microbot platforms to global markets in Europe, North America and Asia.